Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer.[1] It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer.[2] Development was discontinued in 2013.[3][4]
This drug was developed by MedImmune, LLC.[citation needed]
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.
Lokasi Pengunjung: 3.14.128.223